Vaccine Therapy for Pancreatic Cancer: A Battle against Deadly Cancer

Dipesh Kumar Yadav¹, Cai-de Lu¹* and Rajesh Kumar Yadav²

¹Department of Hepatobiliary and Pancreatic Surgery, Lihuili Hospital, Ningbo University, School of Medicine, Ningbo 315060, China
²Department of Pharmacology, Gandaki Medical College, Pokhara, Nepal

Abstract

Pancreatic cancer is one of the deadliest human malignancies and little progress has been achieved in its treatment over the past decades. Historically, chemotherapy or radiotherapy did not provide significant survival benefit in advanced pancreatic cancer. Thus, new therapeutic approaches are needed. As there is strong evidence that vaccine therapy against pancreatic cancer elicits antitumor immune responses, scientists have tried to stimulate the antitumor activities of the immune system to fight against pancreatic cancer, but has not reached to an expected result. Pancreatic cancer activates both antitumor immune responses and immunosuppressive mechanisms leading to tumor development and progression. This action is achieved through mobilization and activation of immune suppressive cells (GAFs), tolerogenic DCs, MDSCs, TAMs, Treg cells and cancer cells-derived soluble factors that promote the induction of tolerance through the generation of CD4+oachin of IL-2R (CD25)+forkhead box P3 (Foxp3) subset. In addition, pancreatic cancer cells modulate the immune system and avoid detection by effector immune by production of immune suppressive cytokines (e.g., TGF-β, IL-10, and IL-6), by expressing surface molecules that mediate immune suppression (e.g., vascular endothelial growth factors (VEGF), Fas ligand (Fas-L), programmed death-1 ligand (PD-L1), indolamine-2, and 3-dioxygenase (IDO). Identification of pancreatic cancer-associated antigens has spurred the development of vaccination-based strategies for treatment. Vaccine therapy relies on the administration of biological preparations that include an antigen that is specifically expressed by malignant cells, boosting the natural ability of the immune system to react against neoplastic cells. Potent vaccines stimulate antigen presentation by dendritic cells, hence driving the expansion of antigen-specific effector and memory T cells. Further, immune modulation and immunosuppressive environment by pancreatic cancer can be overcome by enhancing vaccine efficacy by combinatorial therapy. In this paper, we analyze recent preclinical and clinical efforts towards vaccine therapy for pancreatic cancer designed to target pancreatic cancer-associated antigens and to elicit an antitumor response in vivo.

Keywords: Pancreatic cancer; Immunotherapy; Dendritic cells; Cancer vaccine; MDSCs; Treg

Core Tip: This article includes vaccine therapy strategy for pancreatic cancer and different immunogenic obstacles due dysfunctional immune system in PC leading to tumor development, tumor progression, and resistance to therapy.

Abbreviations: PC: Pancreatic Cancer; FOLFIRINOX: 5-Fluouracil, Leucovorin, Irinotecan and Oxaliplatin; MDSC: Myeloid-Derived Suppressor Cells; Treg: T Regulatory Cells; TME: Tumor Microenvironment; TAMs: Tumor Associated Macrophages; NK Cell: Natural Killer CELLS; CTL: Cytotoxic T Lymphocytete; GM-CSF: Granulocyte-Macrophage Colony-Stimulating Factor; TAAs: Tumor Associated Antigens; DCs: Dendritic Cell; HLA: Human Leukocyte Antigen; MHC: Major Histocompatibility Complex; CpG: C-phosphate-G

Introduction

Pancreatic cancer (PC) is the fourth leading cause of cancer related death in the United States and seventh in the China, with 45,220 new cases in 2013 and estimated 38,460 deaths in the USA [1,2]. Treatment of PC has become multimodal with chemotherapy, radiation and surgical resection in the hope of long term survival. The only chance for cure and long -term survival is microscopic negative margins with R0 surgical resection [3]. However, only 10% to 20% of patients with PC have resectable disease at the time of diagnosis, approximately 30 to 40 percent have locally advanced tumor and another 40 percent will have metastatic disease at the time of diagnosis [1,4], and thus palliative chemotherapy remains the only option for most of these patients [5]. The overall five-year survival probability is less than 5% for all stages combined [1,3,4,6]. Even with advances in surgical techniques most of the patients undergoing a complete surgical resection experience a recurrence [7]. Several autopsy studies suggest that 8%-15% of PC patients die with locally advanced disease and without metastatic spread [8].

There are only a few chemotherapeutic agents that have shown to be effective against PC to date, such as FOLFIRINOX regiment and more recently combination of gemcetabine and erlotinib has shown somehow better result in the treatment of PC [9,10]. The survival benefits for patients treated with these regimens are marginal and hence we are in urgent need of novel therapeutic approaches against PC.

As in recent years, researchers have grown deeper understanding in the field of cancer immunology and their antigens that have given great hope for new alternative treatments for a variety of solid tumors including PC. Emerging evidence supports a critical role for the immune system in PC tumor development, progression and eradication [11,12]. There is strong recent evidence that classical anticancer treatments heavily rely on the immune system for their effectiveness [13-15].

*Corresponding author: LU Cai-de, Department of Hepatobiliary and Pancreatic Surgery, Lihuili Hospital, Ningbo University, School of Medicine, Ningbo 315060, China, Tel: 0086-18858084877; E-mail: lucaide@nbu.edu.cn

Received April 15, 2014; Accepted July 01, 2014; Published July 04, 2014

Citation: Yadav DK, de Lu C, Yadav RK (2014) Vaccine Therapy for Pancreatic Cancer: A Battle against Deadly Cancer. J Cancer Sci Ther 6: 268-277. doi:10.4172/1948-5956.1000281

Copyright: © 2014 Yadav DK, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Desmoplasia and the tumor microenvironment (TME) are increasingly seen as major contributors to chemoresistance in PC [16]. Studies have shown that tumor associated macrophages (TAMs) can influence the response of cancer cells to chemotherapy in the context of a process known as environment-mediated drug resistance [17,18]. Targeting specific immunotherapy could be a revolutionary step in the treatment of PC. In support of the PC-specific immunotherapy approaches, there are many data showing PC patients generates B and T cells specific to antigens expressed on autologous pancreatic tumor cells [19-21]. Antigens expressed in PC cell such as carcinoembryonic antigen (CEA) (over 90%) [22], wilms' tumor gene 1 (WT1) (75%) [23], mucin 1 (MUC1) (over 85%) [24], survivin (77%) [25], human telomerase reverse transcriptase (hTERT) (88%) [26], HER-2/neu (61.2%) [27], p53 (67%) [28], mutated K-RAS (73%) [29] and ß- enolase [30] can be potential targets for immunotherapy. This review summarizes clinical and preclinical efforts towards vaccine strategies and clinical trials for PC.

Dysfunctional Immune System in the PC-Tumor Development and Progression

It has been found that dysfunctional immune system in PC has a critical role in the development and progression of tumor [11,12]. It is known that both the innate and the adaptive immune system are active against human cancers [31]. However, cancer cells escape the innate and adaptive immune responses (immunosurveillance) by immunoselection (selection of nonimmunogenic tumor cell variants, also known as immunoediting) or immunosubversion (active suppression of the immune response) [32]. Anticancer function of the immune system is achieved by cytotoxic CD8 T cells, T helper-1 (Th1) cells, mature dendritic cells (DCs), activated pro-inflammatory macrophages (M1) and NK cells [33]. Under the tumor induced immunosuppressive environment T helper cells acquire a T helper cell type 2 phenotype (Th2), which does not support cytotoxic CD8 T cell responses and is resistance to tumors, macrophages (M1) switch to the immunosuppressive M2 state [34]. In addition, the environment in pancreatic cancer consist of not only cancer cells, but also immune suppressive cells such as cancer-associated fibroblasts (CAFs), tolerogenic DCs, myeloid-derived suppressor cells (MDSCs), immunosuppressive tumor-associated macrophages (TAMs), and T regulatory cells (Treg cells) which inhibit effector immune responses [35]. There are increasing evidences that cancer cells-derived soluble factors promote the induction of tolerance through the generation of CD4+o-chain of IL-2R (CD25)+ forkhead box P3 (Foxp3)+ Treg subset, which is linked to compromised antitumor immune responses [36]. Pancreatic cancer cells modulate the immune system and avoid detection by effector immune by production of immune suppressive cytokines (e.g., TGF-ß, IL-10, and IL-6), by expressing surface molecules that mediate immune suppression (e.g., vascular endothelial growth factors (VEGF), Fas ligand (Fas-L), programmed death-1 ligand (PD-L1), indolamine-2, and 3-dioxygenase (IDO) [35], and interference with MHC class I peptide presentation by down-regulation of MHC class I expression or disabling of the antigen degradation or antigen insertion into the MHC class I [34]. Thus, leading to tumor progression.

Cancer Vaccines Strategies

What determines whether cancer vaccines can become a success in human immunotherapy? Exactly, the same as required for infectious diseases, cancer has to be immunogenic and activate cytotoxic T cell responses. Consequently, cancer cells have to possess immunogenic antigens susceptible of being targeted by vaccination. Cancer vaccines are biological preparations that involve administering a tumor antigen with the aim of stimulating tumor-specific immunity. Antigen can be delivered by a number of ways in the form of whole tumor cell recombinant vaccines, dendritic cell (DC) vaccines that combine antigen with DCs to present to white cells, DNA vaccine by inserting viral, bacterial or yeast DNA into human or animal cells, or T-cell receptor peptide vaccines by inserting peptides to modulate cell-mediated immunity. To be considered an ideal tumor vaccine candidate, expression of the antigen must be restricted to the tumor or only minimally expressed elsewhere in the body. Vaccination against tumor antigens is an attractive approach to adjuvant treatment after surgery, when tumor-induced immune suppression is minimal [37]. Cancer vaccines were first approved for hepatocellular carcinoma and cervical cancer prevention. More recently, the first vaccine (Sipuleucel-T, Provenge) was approved for the treatment of hormone refractory prostate cancer [38].

Compared to all other standard modalities (surgery, chemotherapy, radiotherapy, and adaptive immunotherapy), an effective vaccine-based immune response against tumor may be the only cancer treatment with the potential benefit to last a lifetime. Theoretically, vaccinated patients could mount an immune response able to either cure tumor or keep it under constant restraint (i.e., immune surveillance), delaying tumor recurrence and prolonging survival.

For the development of efficient vaccine researchers have been using different strategies such as:

- Cancer vaccine should seek for Tumor specific antigens and distinct from self-proteins.
- Selection of the appropriate adjuvant, molecules that activate antigen-presenting cells to stimulate an antigen specific cytotoxic T lymphocyte (CTL) mediated immune responses [39].
- Effective vaccine should seek to provide long term memory to prevent tumor recurrence which can activate both innate and adaptive immune systems [40].
- Efforts towards improving the clinical efficacy of immune therapy should involve strategies to neutralize or overcome immune suppression.

Vaccines for Pancreatic Cancer

Several vaccine therapy strategies are being actively tested in clinical trials. An overview of clinical trials in provided in Table 1.

A. Peptide vaccines

Peptide-based cancer vaccines are preparations made from antigenic protein fragments (called epitopes), that represent the minimal immunogenic region of antigens [41,42], designed to enhance the T cell response, especially the CD8. Induction of CTLs needs peptides derived from TAAs to be presented on the surface of APCs (antigens presenting cells), such as DCs, in the context of HLA molecules.

1. KRAS vaccines: The association of mutant Kras with pancreatic cancer was established two decades ago [43,44]. The most common activating point mutation involves the KRAS2 oncogene, on chromosome 12p, in over 90% of PC [45]. This is the highest fraction of K-ras alteration found in any human tumor type. Recent tumor genome sequencing studies has established the prevalence of mutant Kras in Pancreatic Intraepithelial Neoplasia (PanINs), the most common
| Vaccine | Targeting | Phase | Study year and investigators | Number of Pts and Stage of Disease | Name of Antigen | Adjuvant therapy | Result |
|---------|-----------|-------|-------------------------------|-----------------------------------|-----------------|-----------------|--------|
| **Vaccine Therapy for Pancreatic Cancer: A Battle against Deadly Cancer. J Cancer Sci Ther 6: 268-277. doi:10.4172/1948-5956.1000281** |
| **Peptide Vaccine** | | | | | | | |
| **KRAS vaccines** | I/II | Giertsen, et al. [49] | 5 Pts with histologically confirmed PC | Mutated K-ras | GM-CSF | Peptide-specific immunity in 58% of pts. Responder’s median survival 148 vs 61 days for non-responders. 20% long term survivors | |
| | | Weden, et al. [50] | 48 Pts. 10 Surgically resected pts and 38 Pts with advanced disease | Mutated K-ras | GM-CSF | Resulted in an immune response in 2, showed longer survival | |
| | | Abou-Alfa, et al. [51] | 24 Pts with resected PC | Mutated K-ras | GM-CSF | Median recurrence free survival 8.6 months; Median overall survival 20.3 months | |
| **Gastrin vaccines** | I | Gilliam, et al. [59] | 154 Pts with advanced PC, unwilling or unable to take chemotherapy | Gastrin (G17DT) versus placebo | 151 days G17DT vs. 82 days placebo | Median overall survival was 2.2 years | |
| **HSP-peptide complex vaccines** | I | Maki, et al. [60] | 10 Pts with resected PC | HSPCC-96 | - | Median survival time and 1-year survival rate were 6.1 months and 29% | |
| **WT1 vaccine** | I | Nishida, et. al. [61] | 32 Pts with advanced pancreatic cancer | WT1 | Gemcitabine | Median survival time and 1-year survival rate were 6.1 months and 29% | |
| **cancer-testis antigens (CT) vaccine** | I | Okuyama, et al. [70] | 9 Pts with advanced pancreatic cancer | CT and VEGFRs | - | The median overall survival (OS) was 207 days. | |
| **VEGFRs vaccine** | I/II | Gotoh [71] | 17 Unresectable, recurrent or metastatic Pts | VEGF-R1 VEGF-R2 | Gemcitabine | Completed, result not reported yet | |
| | | Bernhardt, et al. [72] | 48 Pts with unresectable PC | Telomerase | GM-CSF | 24/38 With immune responses. Induction of immune response correlated with improved survival | |
| | | Buanes, et al. [73] | 178 Pts with advanced PC | Telomerase | Gemcitabine | No overall survival benefit | |
| | | Crocenzi [74] | 11 Pts with Locally Advanced PC | Telomerase | tadalafil | Ongoing | |
| **Her2/neu vaccine** | I | Morse [75] | 12 Pts with Her2/neu overexpressing tumors, including PC | Her2/neu | - | Median survival time-142 days. Progression free survival time- 56 days. | |
| | | Asahara, et al. [80] | 29 Pts with Advanced PC | KIF20A | - | Median survival time-173 days | |
| | | Suzuki, et al. [81] | 9 Pts with Advanced PC | KIF20A | Gemcitabine | Median survival time-173 days | |
| **Recombinant Vaccines** | III | Arlen, et al. [79] | 255 Metastatic pts following gemcitabine failure | MUC-1, CEA | TRICOM,GM-CSF | No overall survival benefit | |
| **MUC-1 and CEA in poxvirus** | III | Le. et al. [80] | 28 Pts with mesothelioma, lung, pancreas, or ovarian cancer liver metastasis | Mesothelin | - | 37% of patients in Crs-207 arm live after 15 months | |
| **Listeria vaccines** | I | Le. et al. [81] | 90 Pts with metastatic disease | Mesothelin and whole tumor | GM-CSF secreting allogeneic PC cells and cyclophosphamide | Ongoing | |
was 20.3 months [51].

free survival time was 8.6 months and median overall survival time proved to be safe without tumor regression and median recurrence-

pancreatic cancer with K-ras peptide in combination with GM-CSF group also reported that vaccination of 24 patients with resected immune responses and prolonged survival [50]. Moreover, another of mutant K-ras peptides in combination with GMCSF resulted in (10 surgically resected and 38 with advanced disease), vaccination in the study. Among 48 patients with pancreatic cancer derived peptides in unresectable pancreatic cancer patients resulted [46-48]. In a Phase I/II study, the administration of synthetic KRAS-precursor lesions and in pancreatic cancer with increased precision [46-48]. In a Phase I/II study, the administration of synthetic KRAS-derived peptides in unresectable pancreatic cancer patients resulted in an immune response in 2 out of 5 individuals [49]. Since native epitopes have relatively low immunogenicity, granulocyte-macrophage colony-stimulating factor (GM-CSF) was applied to achieve efficient epitopes have relatively low immunogenicity, granulocyte-macrophage colony-stimulating factor (GM-CSF) was applied to achieve efficient

Table 1: Vaccine therapy related clinical trials in pancreatic cancer.

| Vaccine therapy | Study | Phase | Dose and schedule | Outcomes |
|-----------------|-------|-------|-------------------|----------|
| MUC-1 (DCs) vaccines | Lepisto, et al. [82] | I/II | 12 Pts with surgically resected pancreatic (10 pts) or biliary (2 pts) cancer | MUC-1 | 4 Out of 12 pts alive at 4 years |
| LAK cell (DCs) vaccines | Kimura, et al. [83] | | 49 Pts with unresectable PC (Stage III, IVa, IVb) | LAK | Median overall survival of patients receiving DC vaccine and chemotherapy plus LAK cell therapy was longer than those receiving DC vaccine in combination with chemotherapy but no LAK cells |
| Algenpantucel-L | Hardacre, et al. [84] | II | 70 Pts with resected PC | whole tumor | algenpantucel-L with chemotherapy (gemcitabine and 5 FU)+ radiotherapy | 12-month disease-free survival was 62 %, and the 12-month overall survival was 86 % |
| Algenpantucel-L | Multicentered [85] | III | 722 Pts with resected PC (Stage I,II) | whole tumor | algenpantucel-L with chemotherapy (gemcitabine and 5 FU)+ radiotherapy | Ongoing |
| Allogeneic GM-CSF | Jaffee, et al. [86] | I | 14 Pts with resected PC | whole tumor | GM-CSF vaccine with chemoradiotherapy | 3 patients disease free at least 25 months after diagnosis |
| | Lutz, et al. [87] | II | 60 Pts with resected PC | whole tumor | GM-CSF vaccine with chemotherapy (5 FU) and radiotherapy | Disease free survival of 17.3 months and an overall survival of 24.8 months |
| | Laheru [88] | II | 60 Pts with resected PC | whole tumor | GM-CSF secreting allogeneic PC cells, cyclophosphamide and cetuximab | Completed, result not reported yet |
| | Laheru [89] | II | 56 Pts with resected PC | whole tumor | GM-CSF secreting allogeneic PC cells | Ongoing |
| | Laheru [90] | II | 87 Pts with resected PC | whole tumor | GM-CSF secreting allogeneic PC cells and IV vs oral metronomic cyclophosphamide | Ongoing |
| | Herman [91] | I | 18 Pts with resected PC | whole tumor | GM-CSF secreting allogeneic PC cells and cyclophosphamide followed by localized radiation (SBRT) and 5-FU+RIFINOX | Ongoing |

Pancreatic cancer-PC; 5-fluourouracil, leucovorin, irinotecan, and oxaliplatin-FOLFIRINOX; Granulocyte-macrophage colony-stimulating factor- GM-CSF; Dendritic cell-DCs; Carcinoembryonic antigen- CEA, mucin 1-MUC-1; Lymphokine activated killer –LAK; Telomerase reverse transcriptase –hTERT; human epidermal growth factor receptor 2- Her2/neu; vascular endothelial growth factor receptors- VeGFrs; Wilms tumor gene -WT1; Heat shock protein –HSP.

2. Survivin vaccines: Survivin is a member of the inhibitor apoptosis family, which is highly upregulated in most malignancies, including pancreatic cancer [55]. In a study, murine pancreatic and lymphoma models, the survivin DNA vaccine showed significant slow tumor growth and longer survival compared with those vaccinated with vector DNA [56]. In a study, a survivin-derived peptide (AYACNTSTL) was used in combination with IFN α to vaccinate six patients who had advanced pancreatic cancers. Tetramer and enzyme-linked immunosorbent spot (ELISPOT) assays revealed that more than half of the patients had manifested immunological responses to vaccine in combination with gemcitabine, in patients with resected pancreatic cancer, is currently ongoing [53]. Lisiansky et al. selectively kill Ras-transformed cells by over expressing the pro-apoptotic protein, p53 upregulated modulator of apoptosis (PUMA) under a Ras-responsive promoter, and assess it may become a useful, effective and safe approach to selectively target Ras-mutated tumor cells [54].
vaccination, which were often accompanied by clinical benefits [57]. However, this vaccine still needs to be tested in a large population.

3. Gastrin vaccines: Gastrin and cholecystokinin B receptor (CCKBR, also known as CCK-2) are upregulated and co-expressed in both pancreatic cell lines and human PDA specimens and have been implicated in an autocrine, paracrine, and endocrine growth pathway [58]. In a randomized, double-blind, placebo-controlled, group-sequential multicenter trial of G17DT in patients with advanced pancreatic cancer unsuitable for or unwilling to take chemotherapy, resulted in a nearly 2-fold increase in median overall survival, as compared with placebo (151 vs. 82 d, respectively; p=0.03). Anti-gastrin immune responses were noted in 73.8% of the patients and correlated with longer overall median survival versus non responders and placebo (176 vs. 63 vs. 83 days respectively, p=0.003) [59]. Gastrin-based vaccines appear therefore to be well tolerated by and could represent a new therapeutic option for pancreatic cancer.

4. HSP-peptide complex vaccines: Heat shock protein (HSP), a component of HSP–peptide complex (PC), works as a peptide chaperone for stabilizing and delivering peptides. HSP-peptide complexes can be presented on MHC class I molecules on the cell surface. Tumor-derived HSP-peptide complexes have been shown to induce antitumor immune responses in preclinical studies. HSP96-peptide complexes produced from resected tumor tissues were the first to be employed in antigenic vaccines. A phase I pilot trial of patients with resected pancreatic cancer who received no adjuvant radiation or chemotherapy showed the feasibility of preparing HSPCC-96 from the resected tumor. A total of 10 patients were vaccinated with 5 μg of autologous HSPCC-96 weekly for four doses. No dose limiting toxicities were observed. There was no correlation between survival and immune response, exhibiting a median overall survival of 2.2 years. Three of 10 patients were alive without disease at 2.6, 2.7 and 5-years follow up [60]. This study showed that vaccine preparation from resected tumor and the administration were feasible. Further studies need to evaluate the clinical efficacy of HSP vaccines in patients with pancreatic cancer.

5. WT1, cancer-testis antigens (CT) and VEGFRs vaccines: Wilms tumor gene (WT1) protein is an attractive target for cancer immunotherapy, in a study of 32 patients with advanced pancreatic cancer was treated with WT1 vaccine in combination with gemcitabine and was well tolerated. The association between longer survival and positive delayed-type hypersensitivity to WT1 peptide was statistically significant, and longer survivors featured a higher frequency of memory-phenotype WT1-specific cytotoxic T lymphocytes both before and after treatment [61]. Median survival time and 1-year survival rate were 8.1 months and 29% respectively.

The cancer-testis (CT) antigens are expressed by tumors of different histological types at varying frequencies (10–40%) [62]. CT antigens are absent in normal somatic cells in humans and rodents but expressed only in male germ cells (such as spermatogonial stem cells, spermatogonia, spermatocytes, spermatids and spermatozoa) during spermatogenesis in the testis (but not Sertoli and/or Leydig cells) [63-65]. Fifty two percentage of the analyzed pancreatic cancer tissue expressed at least one CT antigen [69]. Recently, in a Phase I clinical trial for advanced pancreatic cancer to investigate the safety, immunostimulatory effects, and antineoplastic activity of a multi-target vaccine composed of four distinct peptides derived from cancer-testis (CT) antigens and vascular endothelial growth factor receptors (VeGFrs) was well-tolerated, and no grade 3 or 4 adverse were observed [70]. The median overall survival (OS) of this cohort was 207 days.

Two vascular endothelial growth factor receptors (VeGFrs) peptide vaccine studies using VEGFR-1 and VEGFR-2 are completed but have not reported results yet [71].

6. Telomerase reverse transcriptase (hTERT) and Her2/neu vaccines: Telomerase reverse transcriptase (hTERT) is a highly immunogenic antigen and has been the target in several vaccination studies. A small phase I/II study in patients with pancreatic cancer showed T cell responses in 63% of vaccinated patients, and prolonged survival in patients exhibiting T cell responses [72]. However, a large phase III study failed to show a survival benefit in pancreatic cancer [73]. Another study is evaluating radiation therapy, tadalafil, sargramostim, gemcitabine and telomerase vaccine (GV1001) in patients with unresectable pancreatic cancer and is currently active and waiting for result [74]. Recently, vaccination against Her2/neu is also being tested in a phase I study in patients with pancreatic cancer [75].

7. KIF20A derived vaccine: Kinesin-like protein KIF20A is a protein that is encoded by the KIF20A gene, KIF20A has been shown to interact with Ras-related protein-RAB6A [76-79]. In a phase I/II trial, HLA-A24-restricted peptide vaccine derived from KIF20A was used for a patient with advanced PC, the trial came to the conclusion that the patients vaccinated with KIF20A-66 peptide had better prognosis than the control group with best supportive care, and concluded that KIF20A-66 vaccination is significantly effective as an immunotherapy against advanced PC [80]. In another phase I clinical trial, KIF20A-derived peptide vaccine with gemcitabine were analyzed and suggested that combination therapy may be feasible and promising for advanced PC [81].

B. Recombinant vaccines

Recombinant vaccines contain bacterial and viral antigen carriers thereby increasing DC activation and improving antigen presentation. They stimulate the innate immune response while efficiently recruiting and activating DCs. The most common carriers include Bacillus Calmette-Guerin (BCG), Listeria monocytogenes (LM), Salmonella and Poxviruses.

1. Carcinoembryonic antigen (CEA) and mucin 1 (MUC-1): The carcinoembryonic antigen (CEA) is an oncofetal antigen that is expressed highly in the majority of pancreatic cancers [82] and MUC-1 is a membrane bound glycoprotein known to promote pancreatic cancer epithelial to mesenchymal transition and invasiveness. It also induces CD8 T cell responses and the production of anti-MUC antibodies are associated with improved survival [83]. TRICOM is a poxvirus-based vaccine containing a combination of three T-cell co-stimulatory molecules: B7-1, intercellular adhesion molecule 1 (ICAM-1) and leukocyte function associated antigen 3 (LFA-3). In a phase I study of TRICOM with CEA vaccine was conducted in 58 patients with metastatic pancreatic cancer by Marshall and colleagues. In this study, the CEA-TRICOM vaccine was used with or without GM-CSF and only one patient had pancreatic cancer. This patient had progressed with increasing pain and CA 19-9 on previous CEA vaccination. After two vaccinations with CEA-TRICOM, CA 19-9 and pain levels decreased for almost 1 year [84]. This study showed that CEA-TRICOM vaccines were safe and generated significant CEA-specific immune response with associated clinical benefit. In a study, yeast-CEA vaccine has been shown to activate DCs when used in murine models [85]. Further, Remondo et al. also showed that Yeast-CEA activates human DCs, which then successfully activated CEA-specific T-cell responses. The CEA-specific T-cell lines were able to lyse human CEA+ pancreatic tumor lines [86]. In a large randomized
phase-III clinical trial of 255 patients, vaccination with a MUC-1 and CEA expressing viral vector showed no overall survival benefits [87]. Interestingly, in a study MUC1-based vaccine in combination with a celecoxib and low-dose gemcitabine was effective in preventing the progression of preneoplastic intraepithelial lesions to invasive PC, further the combination treatment elicited robust antitumor cellular and humoral immune responses and was associated with increased apoptosis in the tumor [88].

2. Listeria vaccines: Listeria monocytogenes (Lm) -based vaccines stimulate both innate and adaptive immunity. In one recent study, patients bearing hepatic metastases from mesothelioma, ovarian cancer, non-small cell lung carcinoma and PC were given this L. monocytogenes strain further engineered to express mesothelin, a cell surface molecule overexpressed by a large majority of PC, mesotheliomas, ovarian cancers, and non-small cell lung carcinomas [89]. Thirty-seven percent of these patients survived 15 months or more. Half of them patients were those harboring metastatic PC, and immunological analyses revealed that they had developed lysteriolysin O- and mesothelin-specific T-cell responses. While a mesothelin vaccine, using genetically modified live attenuated listeria as a vector for the antigen has also entered clinical trial [90].

C. Antigen pulsed dendritic cell (DCs) vaccines

DCs are the most potent antigen presenting cells (APCs) that are capable of priming naïve T cells and can stimulate memory T cells and B cells to generate antigen specific response. Antigen pulsed DCs is another vaccination strategy where patient DCs are isolated, pulsed with peptides, autologous, or allogeneic tumor lysate, or transfected with RNA, and injected back to the patients. In a study of 12 patients (10 with pancreatic cancer), where MUC-1 pulsed DCs were given as adjuvant therapy following resection, 4 of the 12 patients were alive at 4 years [91]. In the second study, a DC-based vaccine alone or combined with Lymphokine activated killer (LAK) cells was administered together with gemcitabine and/or 5-F to 49 patients with advanced pancreatic adenocarcinoma [92]. Median survival in these patients was 360 days. Patients receiving DC vaccine along with chemotherapy and LAK cell therapy had prolonged survival compared with patients who received DC vaccine and chemotherapy. Of all 49 patients, 2 had complete remission, 5 had partial remission and 10 had stable disease. Thus, the study concluded that DC-based vaccine therapy with chemotherapy was shown to be safe and may induce responses.

D. Whole tumor cell vaccines

Whole tumor cell vaccines are another strategy that has shown promise in pancreatic cancer. Autologous whole tumor cells remain a potent vehicle for generating antitumor immunity. This is because tumor cells express all relevant candidate TAAs, including both known and unidentified. Two allogeneic whole cell based anticancer vaccines are currently being investigated for their safety and antineoplastic effects in PC patients.

a. Algenpantucel-L: Algenpantucel-L is the most clinically advanced and promising immunotherapy for pancreatic cancer. Algenpantucel-L (also known as hyperacute-pancreatic cancer vaccine) consists an 2 irradiated, live, human allogeneic pancreatic cancer cell lines that express murine α-1,3-galactosyltransferase, which is responsible for the synthesis of α-galactosylated epitopes on cell surface proteins. Hardacre and colleagues presented the results of an open-label, multi-institutional Phase II clinical trial investigating Algenpantucel-L in combination with standard adjuvant chemoradiotherapy for the treatment of resected PC patients [93]. In this study 69 out of 73 patients were evaluable and they received 100 million cells (N=43) or 300 million cells (N=26) injected intradermally in up to 14 vaccinations. No serious adverse events were attributed to the immunotherapy. After a median follow-up of 21 months, the 12-month disease-free survival was 62%, and the 12-month overall survival was 86%. The most common adverse events were injection site pain and induration. The study concluded that the addition of algenpantucel-L to standard adjuvant therapy for resected pancreatic cancer may improve survival. A multi-institutional, phase 3 study is ongoing (ClinicalTrials.gov identifier, NCT01072981) [94].

b. Allogeneic GM-CSF vaccine therapy: Allogeneic Granulocyte–macrophage colony-stimulating factor (GM-CSF) vaccine therapy, called GVAX, has been tested in a variety of early phase clinical trials. In a phase I clinical study, tumor cells, which were modified to express the immunomodulating cytokine GM-CSF, were given to 14 patients [95]. Three patients had delayed-type hypersensitivity responses to autologous tumor cells and those 3 patients had a longer disease free survival. The Latter, in a phase-II study with a similar approach, 60 patients with resected pancreatic cancer were treated, yielding a disease free survival of 17.3 months and an overall survival of 24.8 months [96].

While the results did not superior result of previous study, other studies using similar approaches, or combining whole tumor vaccination with cyclophosphamide alone, or with conventional chemotherapy, are ongoing [97-100].

Challenges and Enhancing Vaccine Efficacy by Combinatorial therapy

The effective vaccine also should seek to provide long term memory to prevent tumor recurrence [40]. Scientists believe that for total tumor elimination, both the innate and adaptive immune systems should be activated. In current status, immune modulation and immunosuppressive environment by cancer seems to be the major concern and the main challenge for vaccine therapy. One of the means that PC cells evade destruction is through “antigen loss variance”. In a study, Jansen et al. found that tumor recurrence is associated with tumor depigmentation and antigen loss which occurs in immunoediting. However, their studies suggest that even with reduced expression these tumors are still susceptible to antigen-specific antitumor vaccine. Further, their study also demonstrated that targeting Treg and down modulation or removal of the Treg population prior to and/or during immunotherapy may make these cells less susceptible to antigen loss [101].

A tumor can have many different types of cells in it, each with different cell-surface antigens. Vaccine targeting multiple antigens presented by a tumor cell may be advantageous and can enhance vaccine efficacy, but there is a risk of autoimmunity. Though, antigen specific-antitumor vaccine can decrease the risk of autoimmunity because the immune response is directed to a single epitope, tumors may treat and remove the Treg population prior to and/or during immunotherapy may make these cells less susceptible to antigen loss.

As stated earlier, breaking down the immunosuppressive environment of cancer is another need of vaccine therapy for optimization of its efficacy, many researchers has suggested that the
efficacy of vaccine therapy can be enhanced by combinatorial therapy. It has been found that cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and PD1 are two well known co-inhibitory molecules that decreases antitumor responses [103]. In a small clinical trial GM-CSF vaccine along with CTLA4 blockade found increased inflammatory infiltrated and tumor regression [104]. Similarly, in a preclinical study of murine model vaccine was given in combination with PD1 blockade, mice receiving combination therapy had increased overall survival and decreased tumor growth [105]. In one study, it was found that animals treated with vaccine along with antibodies to CTLA4 and PD1 have significantly higher overall survival compared with animals treated with vaccine and either antibody alone, suggesting that combining blockade of multiple inhibitory pathway decreases T cell anergy and improves T cell responsiveness [106]. Many of the preclinical studies have demonstrated that some small molecules targeted therapies in combination with vaccine have the ability to enhance vaccine mediated T cell lysis of tumors. Small molecule inhibitors such as BCL-2 inhibitor, tyrosine kinase inhibitor sunitinib and B-raf inhibitor have been shown to enhance the ratio of expression of TAA-specific T cells to regulatory cells, resulting in enhanced vaccine efficacy [107-111]. Further, radiation therapy (RT) may act synergistically with vaccine therapy to enhance immune responses, inhibit immunosuppression, induction of DNA damage, and/or alter the phenotype of tumor cells, thus rendering them more susceptible to immune-mediated killing [112,113]. It has been found that RT bears the potential to stimulate DC mediated antitumor immunity in this way [112]. Further, it has also been found that the destruction of even a small percentage of tumor cells by radiation could result in cross-priming and presentation of tumor antigens to the immune system, thereby potentiating antitumor responses [114]. The challenge for now is how to exploit radiation-induced changes in tumor-cell antigens and how to induce effective immune responses to these cumulatively immunogenic stimuli.

Recently, Vaccine has also been used with other combinatorial therapies like hormonal, monoclonal antibodies and chemotherapy; many of these preclinical and clinical studies have shown potential benefits over the vaccine therapy alone.

**Logical Problems for Vaccine Therapy**

Most clinical trials investigating a cancer vaccine have failed or had very modest responses, possible because of the following reasons: It is hard to treat advanced disease stage or bulky tumor with vaccines, because bulky tumor actively suppresses the immune system. The most suitable stage for a cancer vaccine is likely to be early disease or after de-bulking of the tumor by surgery, chemotherapy or by radiotherapy [37]. Antigen specific anti-tumor vaccines are more at risk for antigen loss variance. Cancer vaccines that target just one tumor antigen are likely to be less effective. The most effective cancer vaccine is likely to raise an immune response against multiple tumor antigens to minimize the chance of the tumor being able to mutate and become resistant to the therapy [102]. But vaccines targeting multiple tumor antigens may increase the risk of autoimmunity [115]. Numerous clinical trials carried out in the past have treated patients who have received numerous cycles of chemotherapy. As chemotherapy, is often myelosuppressive and immunosuppressive. So, there is little point of giving a cancer vaccine to a patient who is immune suppressed. It may take some times for vaccine to show an immune response and thus, vaccine may not be suitable for the highly malignant tumors like pancreatic cancer that can produce marked clinical deterioration, or even death, within this time period.

**Perspectives**

Although vaccine therapy as a single agent has encouraging results, clinical trials in PC patients have been underwhelming and disappointing. Most of these clinical studies identified a number of critical aspects that must be carefully considered in the design the next generation of cancer vaccines. As stated earlier dysfunctional immune system in PC further give rise to tumor induced immunosuppressive environment has a critical role in the development and progression of tumor. Which consist of not only cancer cells, but also immune suppressive cells (CAFs, tolerogenic DCs, MDSCs, TAMs and Treg cells) and cancer cells-derived soluble factors that promote the induction of tolerance. So, the novel vaccine therapy strategy should be designed for breaking immunosuppression within the tumor microenvironment, to inhibit immunologic checkpoint blockade and to modulate tumor microenvironment. Thus, this may require a combinatorial therapeutic approach which includes chemotherapy, radiation, surgery and immunotherapy.

**Conflict of Interests**

The author declares no conflict of interests.

**Fund support**

The Scientific Innovation Team Project of Ningbo (Fund number-2013B82010).

**References**

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30.
2. Chen W, Zheng R, Zhang S, Zhao P, Li G, et al. (2013) The incidences and mortalities of major cancers in China, 2009. Chin J Cancer 32: 106-112.
3. Wellner UF, Makowiec F, Bausch D, Höppner J, Sick O, et al. (2012) Locally advanced pancreatic head cancer: margin-positive resection or bypass? ISRN Surg 2012: 513241.
4. Assil MM, Lu X, Ebi G, Reber HA, Li G, et al. (2011) Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery 150: 466-473.
5. Shrikhande SV, Kleeff J, Reiser C, Weitz J, Hinz U, et al. (2007) Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol 14: 118-127.
6. Bose D, Katz MHG, Fleming JB (2012) Pancreatic Adenocarcinoma. In: Feig BW, Ching CD, editors. The MD Anderson Surgical Oncology Handbook. 5th ed. Philadelphia: Lippincott Williams and Wilkins; pp. 472-490.
7. Pérez D, Labonte MJ, Lenz HJ (2012) Pancreatic cancer: medical management (novel chemotherapeutics). Gastroentrol Clin North Am 41: 189-209.
8. Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, et al. (2009) DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 27: 1806-1813.
9. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, et al. (2011) FOLFRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl Med 364: 1817-1825.
10. Diaz Beveridge R, Alcolea V, Aparicio J, Segura Á, García J, et al. (2014) Management of advanced pancreatic cancer with gemcitabine plus erlotinib: efficacy and safety results in clinical practice. JOP 15: 19-24.
11. Yokokawa J, Palena C, Arlen P, Hassan R, Ho M, et al. (2005) Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Cancer Res 11: 6342-6351.
12. Johnston FM, Tan BR Jr, Porembka MR, Brunt EM, et al. (2009) Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer. Clin Cancer Res 15: 6511-6518.
13. Arce F, Koohan G, Breckpot K, Stephenson H, Escors D (2012) Selective activation of intracellular signalling pathways in dendritic cells for cancer immunotherapy. Anticancer Agents Med Chem 12: 29-39.
14. Ghiiringhelli F, Bruchard M, Apetoh L (2013) Immune effects of 5-fluorouracil: Ambivalence matters. Oncoimmunology 2: e23139.

15. Ghiiringhelli F, Apetoh L (2013) Chemotherapy and immunomodulation: from immunogenic chemotherapies to novel therapeutic strategies. Future Oncol 9: 469-472.

16. Authors Whatcott CJ, Posner RG, Von Hoff DD, Han H ($) Desmoplasia and chemoresistance in pancreatic cancer. Desmoplasia and chemoresistance in pancreatic cancer.

17. De Palma M, Lewis CE (2011) Cancer: Macrophages limit chemotherapy. Nature 472: 303-304.

18. Mitchem JB, Brennan DJ, Knoboff BL, Belt BA, Zhu Y, et al. (2013) Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapy responses. Cancer Res 73: 1128-1141.

19. Kubschok B, Neumann F, Bretl R, Sester M, Schormann C, et al. (2006) Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer. Clin Cancer Res 12: 1365-1372.

20. Yanagimoto H, Mine T, Yamamoto K, SATO S, Terakawa N, et al. (2007) Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer. Cancer Sci 98: 605-611.

21. Wenandy L, Sørensen RB, Sengelov L, Svane IM, thor Straten P, et al. (2008) The immunogenicity of the hTERT540-548 peptide in cancer. Clin Cancer Res 14: 4-7.

22. Yamaguchi K, Enjoji M, Tsuneyoshi M (1991) Pancreatoduodenal adenocarcinoma: a clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA19-9. J Surg Oncol 47: 148-154.

23. Oj Y, Nakamori S, Fujikawa M, Nakatsuka S, Yokota A, et al. (2004) Overexpression of the Wnts’ tumor gene WT1 in pancreatic ductal adenocarcinoma. Cancer Sci 95: 583-587.

24. Ueda M, Miura Y, Kunihiro O, Ishikawa T, Ichikawa Y, et al. (2005) MUC1 overexpression is the most reliable marker of invasive carcinoma in intraductal papillary-mucinous tumor (IPMT). Hepatogastroenterology 52: 398-403.

25. Wobser M, Keikavoussi P, Kunzmann V, Weininger M, Anderson MH, et al. (2006) Complete remission of liver metastasis of pancreatic cancer under vaccination with a HILA-A2 restricted peptide derived from the universal tumor vaccina.

26. Seki K, Suda T, Aoyagi Y, Sugawara S, Natsui M, et al. (2004) Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer. Clin Cancer Res 12: 1365-1372.

27. Nakata M, Nakata B, Amano R, Yamada N, Yashiro M, et al. (2009) HER2 overexpression correlates with survival after curative resection of pancreatic cancer. Cancer Sci 100: 1243-1247.

28. Maacke H, Kessler A, Schmiegel W, Roeder C, Vogel I, et al. (1997) Overexpression of p53 protein during pancreatitis. Br J Cancer 75: 1501-1504.

29. Gjertsen MK, Bakka A, Breivik J, Sæterdal I, Solheim BG, et al. (1995) Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet 346: 1399-1400.

30. Cappello P, Tomaino B, Chiarle R, Ceruti P, Novarino A, et al. (2009) An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen. Int J Cancer 125: 639-648.

31. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454: 436-444.

32. Zitvogel L, Apetoh L, Ghiiringhelli F, Andé F, Tesnière A, et al. (2008) The anti-cancer immune response: indispensable for therapeutic success? J Clin Invest 118: 1991-2001.

33. Bracci L, Schiavoni G, Sistigu A, Belardelli F (2014) Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationate- based combined treatments against cancer. Cell Death Differ 21: 15-25.

34. Sideras K, Braat H, Kwakkeboom J, van Eijck CH, Peppelienbosch MP, et al. (2014) Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. Cancer Treat Rev 40: 513-522.

35. Koido S, Homma S, Hara E, Namiki Y, Takahara A, et al. (2010) Regulation of tumor immunity by tumor/dendritic cell fusions. Clin Dev Immunol 2010: 516766.

36. Koido S, Homma S, Hara E, Mitsunaga M, Namiki Y (2008) In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells. J Transl Med 6: 51.

37. Shakhar G, Ben-Eliyahu S (2003) Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol 10: 972-992.

38. Shapiro D, Tareen B (2012) Current and emerging treatments in the management of castration-resistant prostate cancer. Expert Rev Anticancer Ther 12: 951-964.

39. Palena C, Abrams SI, Schlom J, Hodge JW (2006) Cancer vaccines: preclinical studies and novel strategies. Adv Cancer Res 95: 115-145.

40. Pejzajar-Gaddy S, Finn OJ (2008) Cancer vaccines: accomplishments and challenges. Crit Rev Oncol Hematol 67: 93-102.

41. Purcell AW, McCluskey J, Rossjohn J (2007) More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 6: 404-414.

42. Bijker MS, Melef CJ, Offringa R, van der Burg SH (2007) Design and development of synthetic peptide vaccines: past, present and future. Expert Rev Vaccines 6: 591-603.

43. Smit VT, Bot AJ, Smits AM, Fleuren GJ, Cornelisse CJ, et al. (1988) KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 16: 7773-7782.

44. Almoguera C, Shibata D, Forrester K, Martin J, Arnhem N, et al. (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53: 549-554.

45. Palyaeve-Gupta Y, Grabacka E, Bar-Sagi D (2011) RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 11: 761-774.

46. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Humphswamy LB, et al. (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491: 399-405.

47. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-1806.

48. Kanda M, Matthaei H, Wu J, Hong SM, Yu J, et al. (2012) Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 142: 730-733.

49. Gjertsen MK, Bakka A, Breivik J, Sæterdal I, Solheim BG, et al. (1995) Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet 346: 1399-1400.

50. Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, et al. (2001) Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 92: 441-450.

51. Abou-Alfa GK, Chapman PB, Feilchenfeld J, Brennan MF, Capanu M, et al. (2011) Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine. Am J Clin Oncol 34: 321-325.

52. Weden S, Klimp M, Gladhaug IP, Moller M, Eriksen JA, et al. (2011) Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int J Cancer 128: 1120-1129.

53. Globelimmune (2014) Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-Metastatic, Post-resection Pancreas Cancer. ClinicalTrials.gov: NCT00300950.

54. Lisiansky V, Naumov I, Shapiro S, Kazanov D, Starr A, et al. (2012) Gene therapy of pancreatic cancer targeting the K-Ras oncogene. Cancer Gene Ther 19: 862-869.

55. Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, et al. (2001) Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic ductal cell tumors. Cancer 92: 271-278.

56. Zhu K, Qin H, Cha SC, Neslappu SS, Overwijk W, et al. (2007) Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. Vaccine 25: 7959-7961.
Citation: Yadav DK, de Lu C, Yadav RK (2014) Vaccine Therapy for Pancreatic Cancer: A Battle against Deadly Cancer. J Cancer Sci Ther 6: 268-277. doi:10.4172/1948-5666.1000281

57. Kameshima H, Tsuruma T, Kutomi G, Shima H, Iwayama Y, et al. (2013) Immunotherapeutic benefit of α-interferon (IFN-α) in surviving2B-derived peptide vaccination for advanced pancreatic cancer patients. Cancer Sci 104: 124-129.

58. Monstein HJ, Ohlsborn B, Axelson J (2001) Differential expression of gastrin, cholecystokinin-A and cholecystokinin-B receptor mRNA in human pancreatic cancer cell lines. Scand J Gastroenterol 36: 738-743.

59. Gilliam AD, Broome P, Topuzov EG, Garin AM, Pulya I, et al. (2012) An international multicenter randomized controlled trial of G17DT in patients with pancreatic cancer. Pancreas 41: 374-379.

60. Maki RG, Livingston PO, Lewis JJ, Janetzi S, Klimstra D, et al. (2007) A phase I pilot study of autologous heat shock protein vaccine HISP2P-96 in patients with resected pancreatic adenocarcinoma. Dig Dis Sci 52: 1964-1972.

61. Nishida S, Koido S, Takeda Y, Homma S, Komita H, et al. (2014) Peptide-based Cancer Vaccine Combined with Gemcitabine for Patients with Advanced Pancreatic Cancer. J Immunotherapy 37: 105-114.

62. Van den Eynde SJ, Boon T (1997) Tumor antigens recognized by T lymphocytes. Int J Clin Lab Res 27: 81-86.

63. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT (2002) Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunn Rev 188: 22-26.

64. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ (2005) Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5: 615-625.

65. Miranda L, J Cannon M, Cobos E, Bernardini G, Jenkins MR, et al. (2011) Cancer testsis antigens: novel biomarkers and targetable proteins for ovarian cancer. Int Rev Immunol 30: 127-137.

66. Cebon J (2010) Cancer vaccines: Where are we going? Asia Pac J Clin Oncol 6 Suppl 1: S9-15.

67. Akers SN, Lyerly (2014) A Phase I Study To Evaluate The Antitumor Activity And Immunologic Evaluation of Dendritic Cell-Based Immunotherapy in Combination with Gemcitabine and Bevacizumab in Patients with Advanced Pancreatic Cancer. J Immunotherapy 37: 105-114.

68. Sukizaki N, Hara Y, Sasaki T, Komaki S, Matsuo K, et al. (2014) Immunotherapeutic benefit of α-interferon (IFN-α) in surviving2B-derived peptide vaccination for advanced pancreatic cancer patients. Cancer Sci 104: 124-129.

69. Asahara S, Takeda K, Yamao K, Maguchi H, Yamaue H (2013) Phase II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer. J Trans Med 11: 291.

70. Suzuki N, Hazama S, Ueno T, Matsu Y, Shindo Y, et al. (2014) A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer. J Immunother 37: 36-42.

71. Gunturu KS, Rossai GR, Saff MW (2013) Immunotherapy updates in pancreatic cancer: are we there yet? Ther Adv Med Oncol 5: 81-89.

72. Hamanaka Y, Suehiro Y, Fukui M, Shikichi K, Imai K, et al. (2003) Circulating and high U1G Ig antibody as a favorable prognostic factor for pancreatic cancer. Int J Cancer 103: 97-100.

73. Marshall JL, Gulley JL, Arlen PM, Beetham PK, Tsang KY, et al. (2005) Phase I/II study of sequential vaccinations with fowlpoxCEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 23: 720-731.

74. Bernstein MB, Chakraborty M, Wansley EK, Guo Z, Franzusoff A, et al. (2008) Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells. Vaccine 26: 509-521.

75. Remondo C, Cereda V, Mostböck S, Sabzevari H, Franzusoff A, et al. (2009) Human dendritic cell maturation and activation by a heat-killed recombinant yeast (Saccharomyces cerevisiae) vector encoding carcinoembryonic antigen. Vaccine 27: 987-994.

76. Arlen PM, Gulley JL, Madian RA, Hodge JW, Schiom J (2007) Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. Crit Rev Immunol 27: 451-462.

77. Mukeherjee P, Basu GD, Tindel TL, Subramani DB, Bradley JM, et al. (2009) Progression of pancreatic adenocarcinoma is significantly impeded by a combination of vaccine and COX-2 inhibition. J Immunol 182: 216-224.

78. Le DT, Brockett DG, Nir-Paz R, Hampl J, Mathur S, et al. (2012) A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res 18: 858-868.

79. Takashi Kimura (2013) Antiangiogenic Peptide Vaccine Therapy with Gemicitabine in Treating Patient with Pancreatic Cancer (Phase1/2). ClinicalTrials.gov: NCT00655785.

80. Lepistö AJ, Moser AJ, Zeh H, Lee K, Bartlett D, et al. (2008) A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther 6: 955-964.

81. Takashi Kimura, Y, Tsukada T, Tomoda T, Takahashi H, Imai K, et al. (2012) Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or 5-FU in patients with advanced pancreatic carcinoma. Panreas 41: 195-205.

82. Hardacre JM, Mulcahy M, Small W, Talamonti M, Obel J, et al. (2013) Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. J Gastrointest Surg 17: 94-100.

83. Immunotherapy Study for Surgically Resected Pancreatic Cancer. ClinicalTrials.gov: NCT01702981.

84. Jaaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, et al. (2001) Novel allologic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 19: 145-156.

85. Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, et al. (2011) A lethally irradiated allologic granulocyte&macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A phase II trial of safety, efficacy, and immune activation. Ann Surg 253: 328-335.

86. Daniel A. Laheru (2011) Vaccine Therapy, Cyclophosphamide, and Cetuximab for Surgically Resected Pancreatic Cancer. ClinicalTrials.gov: NCT00305789.

87. Sidney Kimmel Comprehensive Cancer Center (2011) Vaccine Therapy in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer. J Cancer Sci Ther 6: 268-277. doi:10.4172/1948-5666.1000281
99. Sidney Kimmel Comprehensive Cancer Center (2014) Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery. ClinicalTrials.gov: NCT00727441.

100. Sidney Kimmel Comprehensive Cancer Center (2012) Pancreatic Tumor Cell Vaccine (GVAX), Low Dose Cyclophosphamide, Fractionated Stereotactic Body Radiation Therapy (SBRT), and FOLFIRINOX Chemotherapy in Patients with Resected Adenocarcinoma of the Pancreas. ClinicalTrials.gov: NCT01595321.

101. Jensen SM, Twitty CG, Maston LD, Antony PA, Lim M, et al. (2012) Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrence. J Immunol 189: 767-776.

102. Pejawar-Gaddy S, Finn OJ (2008) Cancer vaccines: accomplishments and challenges. Crit Rev Oncol Hematol 67: 93-102.

103. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264.

104. Li B, VanRoey M, Wang C, Chen TH, Korman A, et al. (2009) Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Cancer Res 15: 1623-1634.

105. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, et al. (2008) Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 105: 3005-3010.

106. Curran MA, Montalvo W, Yagita H, Allison JP (2010) PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 107: 4275-4280.

107. Farsaci B, Sabzevari H, Higgins JP, Di Bari MG, Takai S, et al. (2010) Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine. Int J Cancer 127: 1603-1613.

108. Finke JH, Rini B, Ireland J, Rayman P, Richmond A, et al. (2008) Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 14: 6674-6682.

109. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, et al. (2009) Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 15: 2148-2157.

110. Farsaci B, Higgins JP, Hodge JW (2012) Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer 130: 1948-1959.

111. Boni A, Cogdill AP, Deng P, Udayakumar D, Njauw CN, et al. (2010) Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 70: 5213-5219.

112. Rubner Y, Wunderlich R, Rühle PF, Kulzer L, Werthmüller N, et al. (2012) How does ionizing irradiation contribute to the induction of anti-tumor immunity? Front Oncol 2: 75.

113. Frey B, Rubner Y, Kulzer L, Werthmüller N, Weiss EM, et al. (2014) Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunol Immunother 63: 29-36.

114. Hodge JW, Guha C, Neefjes J, Gulley JL (2008) Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park) 22: 1064-1070.

115. Amos SM, Duong CP, Westwood JA, Ritchie DS, Junghans RP, et al. (2011) Autoimmunity associated with immunotherapy of cancer. Blood 118: 499-509.